Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China

BACKGROUND: Dasatinib and imatinib are the recommended tyrosine kinase inhibitors (TKIs) for treating pediatric Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL), and the one which has been approved indication in China is imatinib. Recently, clinical demand for Ph + ALL treatment is beco...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Wang, Yu, Yuncui, Qiu, Yingpeng, Liu, Lu, Zhang, Hao, Shi, Liwei, Xiao, Yue, Jia, Lulu, Zhang, Ruidong, Wang, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791740/
https://www.ncbi.nlm.nih.gov/pubmed/36567324
http://dx.doi.org/10.1186/s12913-022-08971-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791740/
https://www.ncbi.nlm.nih.gov/pubmed/36567324
http://dx.doi.org/10.1186/s12913-022-08971-7

Ejemplares similares